LRRK2-Knockout Microglia Cell Line

This microglia cell line features a stable knockout of leucine-rich repeat kinase 2 (LRRK2). Mutations in LRRK2 are the major genetic cause of autosomal-dominantly inherited Parkinson’s disease.This modification allows for in-depth studies on LRRK2’s functions within microglia, the brain’s resident immune cells, and its impact on neuroinflammation and neuronal signaling. Utilized primarily in neurodegenerative research, this cell line facilitates exploration of LRRK2’s involvement in microglial activation, cytokine production, and phagocytic activities, providing insights into the mechanisms that potentially contribute to disease progression. It serves as a crucial tool for developing therapeutic strategies targeting microglial functions in Parkinson’s disease and for broader applications in studying the molecular underpinnings of neuroinflammation and immune responses in the central nervous system.Note: this product is exclusively available for sale to end users located in China. For inquiries, please contact:镇江爱必梦生物科技有限公司江苏省镇江市京口区国家大学科技园中心研发区B14栋邮编212009Tel: 0511-83367989Fax: (0511)8336-7989Email: order.china@abmGood.com